280574-41-6

Upstream product

• 108-24-7 acetic anhydride 

Downstream Products

• 280574-43-8 N⁶-benzoyl-9-[5-O-benzyl-3-deoxy-3-(3-O-benzyl-4,5,7-tri-O-acetyl-2,6-anhydro-1-deoxy-D-glycero-D-ido-heptitol-1-yl)-β-D-ribo-pentofuranosyl]adenine 
• 289044-99-1 1-[5-O-benzyl-3-deoxy-3-(3-O-benzyl-7-O-trityl-2,6-anhydro-1-deoxy-D-glycero-D-ido-heptitol-1-yl)-β-D-ribo-pentofuranosyl]uracil 
• 280574-44-9 N⁶-benzoyl-9-[5-O-benzyl-3-deoxy-3-(3-O-benzyl-7-O-trityl-2,6-anhydro-1-deoxy-D-glycero-D-ido-heptitol-1-yl)-β-D-ribo-pentofuranosyl]adenine 
• 289044-98-0 1-[5-O-benzyl-3-deoxy-3-(3-O-benzyl-4,5,7-tri-O-acetyl-2,6-anhydro-1-deoxy-D-glycero-D-ido-heptitol-1-yl)-β-D-ribo-pentofuranosyl]uracil 

Relevant academic research and scientific papers

Synthesis of the C-glycosidic analog of adenophostin A, a potent IP3 receptor agonist, using a temporary silicon-tethered radical coupling reaction as the key step

Synthesis of the C-glycosidic analog (3) of adenophostin A, a very potent IP3 receptor agonist, was achieved using a temporary silicon-tethered reductive radical coupling reaction as the key step. Radical reaction of the silaketal substrate 6 with Bu3SnH/AIBN in benzene occurred stereoselectively, and subsequent desilylation gave the desired C-glycosidic disaccharide 7 with the (3α,1'α-configuration as the major product. Compound 7 was converted into the target 3 via the introduction of an adenine base by a Vorbruggen glycosylation reaction. (C) 2000 Elsevier Science Ltd.